John Varga, MDJohn and Nancy Hughes Distinguished ProfessorFeinberg School of MedicineDirector, Northwestern Scleroderma ProgramChicago, Illinois, USA​ Christopher P. Denton, PhD, FRCP Professor of Experimental Rheumatology Centre for Rheumatology and Connective Tissue Diseases Division of MedicineUniversity College London London, United Kingdom Fredrick M. Wigley, MD Martha McCrory Professor of Medicine Department of Medicine/Rheumatology The Johns Hopkins University School of Medicine Baltimore, Maryland, USA Yannick Allanore, MD Service de Rhumatologie A Université Paris Descartes, Hôpital Cochin Paris, France Masataka Kuwana, MD, PhD Professor Department of Allergy and Rheumatology Nippon Medical School GraduateSchool of Medicine Tokyo, Japan

• Section I. Introduction.- Historical Perspective of Scleroderma.- Section II. Epidemiology, Genetics and Classification.- Epidemiology, Environmental and Infectious Risk Factors.- Genetic Factors.- Disease Subsets in Clinical Practice.- Evolving Concepts of Diagnosis and Classification.- Overlap Syndromes.- Juvenile Localized and Systemic Scleroderma.- Morphea (Localized Scleroderma).- Scleroderma Mimics.- Systems Biology Approaches to Understanding the Pathogenesis of Systemic Sclerosis.- Section III: The Biological Basis of Systemic Sclerosis.- Introduction: The Etiopathogenesis of Systemic Sclerosis: An Integrated Overview.- Pathology of Systemic Sclerosis.- Inflammation and Immunity.- Autoantibodies as Markers and Possible Mediators of Scleroderma Pathogenesis.- The Clinical Aspects of Autoantibodies.- Mechanisms of Vascular Disease.- Biomarkers in Systemic Sclerosis.- Pathophysiology of Fibrosis in Systemic Sclerosis.- Overview of Animal Models.- Section IV. Cardiovascular Manifestations and Management.- Raynaud’s Phenomenon, Digital Ulcers, and Nailfold Capillaroscopy.- Renal Crisis and Other Renal Manifestations of Scleroderma.- Cardiac Involvement.- Section V. Pulmonary Manifestations and Management.- Overview of Lung Involvement: Diagnosis, Differential Diagnosis, and Monitoring.- Clinical Assessment of Lung Disease.- Treatment of Interstitial Lung Disease.- Pathogenesis of Pulmonary Arterial Hypertension.- Clinical Assessment of Pulmonary Hypertension.- The Management of Pulmonary Arterial Hypertension in the Setting of Systemic Sclerosis.- Section VI. Gastrointestinal Manifestations and Management.- Overview of Gastrointestinal Tract Involvement.- Upper Gastrointestinal Tract: Manifestations of Systemic Sclerosis.- Small and Large Intestinal Involvement and Nutritional Issues.- Section VII. Skin, Musculoskeletal and Other Complications.- Calcinosis.- Evaluation and Management of Skin Disease.- Assessment and Management of Progressive Skin Involvement in Diffuse Scleroderma.- Skeletal Muscle Involvement.- Tendons, Joints, and Bone.- Cancer in Systemic Sclerosis.- Overlooked  Manifestations.- Pregnancy.- Section VIII:  Management and Outcome Assessment.- Introduction to Section VIII: Management and Outcome Assessment.- Immunomodulatory, Immunoablative, and Biologic Therapies.- Investigative Approaches to Drug Therapy.- Drug Development and Regulatory Considerations for SSc Therapies.- Physical and Occupational Therapy.- Psychosocial Issues and Care for Patients with Systemic Sclerosis.- Clinical Trial Design in Systemic Sclerosis.- Measuring Disease Activity and Outcomes in Clinical Trials.- Innovative Approaches to Clinical Trials in Systemic Sclerosis.- Molecular Stratification by Gene Expression as a Paradigm for Precision Medicine in Systemic Sclerosis.- Section IX. Case Studies: Approach to Complex Clinical Problems.- Managing the Ischemic Finger in Scleroderma.- Scleroderma Renal Crisis.- Rapid Diffuse Skin Disease with Progressive Joint Contractures.- Management of the Scleroderma Patient with Pulmonary Arterial Hypertension Failing Initial Therapy.- Pseudo-obstruction with Malabsorption and Malnutrition.- Progressive Interstitial Lung Disease Non-Response to Cyclophosphamide.- Coping with the Disfigurement of Scleroderma: Facial, Skin, and Hand Changes.- Managing Complicated Digital Ulcers

John Varga, MDJohn and Nancy Hughes Distinguished ProfessorFeinberg School of MedicineDirector, Northwestern Scleroderma ProgramChicago, Illinois, USA​ Christopher P. Denton, PhD, FRCP Professor of Experimental Rheumatology Centre for Rheumatology and Connective Tissue Diseases Division of MedicineUniversity College London London, United Kingdom Fredrick M. Wigley, MD Martha McCrory Professor of Medicine Department of Medicine/Rheumatology The Johns Hopkins University School of Medicine Baltimore, Maryland, USA Yannick Allanore, MD Service de Rhumatologie A Université Paris Descartes, Hôpital Cochin Paris, France Masataka Kuwana, MD, PhD Professor Department of Allergy and Rheumatology Nippon Medical School GraduateSchool of Medicine Tokyo, Japan

• Section I. Introduction.- Historical Perspective of Scleroderma.- Section II. Epidemiology, Genetics and Classification.- Epidemiology, Environmental and Infectious Risk Factors.- Genetic Factors.- Disease Subsets in Clinical Practice.- Evolving Concepts of Diagnosis and Classification.- Overlap Syndromes.- Juvenile Localized and Systemic Scleroderma.- Morphea (Localized Scleroderma).- Scleroderma Mimics.- Systems Biology Approaches to Understanding the Pathogenesis of Systemic Sclerosis.- Section III: The Biological Basis of Systemic Sclerosis.- Introduction: The Etiopathogenesis of Systemic Sclerosis: An Integrated Overview.- Pathology of Systemic Sclerosis.- Inflammation and Immunity.- Autoantibodies as Markers and Possible Mediators of Scleroderma Pathogenesis.- The Clinical Aspects of Autoantibodies.- Mechanisms of Vascular Disease.- Biomarkers in Systemic Sclerosis.- Pathophysiology of Fibrosis in Systemic Sclerosis.- Overview of Animal Models.- Section IV. Cardiovascular Manifestations and Management.- Raynaud’s Phenomenon, Digital Ulcers, and Nailfold Capillaroscopy.- Renal Crisis and Other Renal Manifestations of Scleroderma.- Cardiac Involvement.- Section V. Pulmonary Manifestations and Management.- Overview of Lung Involvement: Diagnosis, Differential Diagnosis, and Monitoring.- Clinical Assessment of Lung Disease.- Treatment of Interstitial Lung Disease.- Pathogenesis of Pulmonary Arterial Hypertension.- Clinical Assessment of Pulmonary Hypertension.- The Management of Pulmonary Arterial Hypertension in the Setting of Systemic Sclerosis.- Section VI. Gastrointestinal Manifestations and Management.- Overview of Gastrointestinal Tract Involvement.- Upper Gastrointestinal Tract: Manifestations of Systemic Sclerosis.- Small and Large Intestinal Involvement and Nutritional Issues.- Section VII. Skin, Musculoskeletal and Other Complications.- Calcinosis.- Evaluation and Management of Skin Disease.- Assessment and Management of Progressive Skin Involvement in Diffuse Scleroderma.- Skeletal Muscle Involvement.- Tendons, Joints, and Bone.- Cancer in Systemic Sclerosis.- Overlooked  Manifestations.- Pregnancy.- Section VIII:  Management and Outcome Assessment.- Introduction to Section VIII: Management and Outcome Assessment.- Immunomodulatory, Immunoablative, and Biologic Therapies.- Investigative Approaches to Drug Therapy.- Drug Development and Regulatory Considerations for SSc Therapies.- Physical and Occupational Therapy.- Psychosocial Issues and Care for Patients with Systemic Sclerosis.- Clinical Trial Design in Systemic Sclerosis.- Measuring Disease Activity and Outcomes in Clinical Trials.- Innovative Approaches to Clinical Trials in Systemic Sclerosis.- Molecular Stratification by Gene Expression as a Paradigm for Precision Medicine in Systemic Sclerosis.- Section IX. Case Studies: Approach to Complex Clinical Problems.- Managing the Ischemic Finger in Scleroderma.- Scleroderma Renal Crisis.- Rapid Diffuse Skin Disease with Progressive Joint Contractures.- Management of the Scleroderma Patient with Pulmonary Arterial Hypertension Failing Initial Therapy.- Pseudo-obstruction with Malabsorption and Malnutrition.- Progressive Interstitial Lung Disease Non-Response to Cyclophosphamide.- Coping with the Disfigurement of Scleroderma: Facial, Skin, and Hand Changes.- Managing Complicated Digital Ulcers

John Varga, MDJohn and Nancy Hughes Distinguished ProfessorFeinberg School of MedicineDirector, Northwestern Scleroderma ProgramChicago, Illinois, USA​ Christopher P. Denton, PhD, FRCP Professor of Experimental Rheumatology Centre for Rheumatology and Connective Tissue Diseases Division of MedicineUniversity College London London, United Kingdom Fredrick M. Wigley, MD Martha McCrory Professor of Medicine Department of Medicine/Rheumatology The Johns Hopkins University School of Medicine Baltimore, Maryland, USA Yannick Allanore, MD Service de Rhumatologie A Université Paris Descartes, Hôpital Cochin Paris, France Masataka Kuwana, MD, PhD Professor Department of Allergy and Rheumatology Nippon Medical School GraduateSchool of Medicine Tokyo, Japan

• Section I. Introduction.- Historical Perspective of Scleroderma.- Section II. Epidemiology, Genetics and Classification.- Epidemiology, Environmental and Infectious Risk Factors.- Genetic Factors.- Disease Subsets in Clinical Practice.- Evolving Concepts of Diagnosis and Classification.- Overlap Syndromes.- Juvenile Localized and Systemic Scleroderma.- Morphea (Localized Scleroderma).- Scleroderma Mimics.- Systems Biology Approaches to Understanding the Pathogenesis of Systemic Sclerosis.- Section III: The Biological Basis of Systemic Sclerosis.- Introduction: The Etiopathogenesis of Systemic Sclerosis: An Integrated Overview.- Pathology of Systemic Sclerosis.- Inflammation and Immunity.- Autoantibodies as Markers and Possible Mediators of Scleroderma Pathogenesis.- The Clinical Aspects of Autoantibodies.- Mechanisms of Vascular Disease.- Biomarkers in Systemic Sclerosis.- Pathophysiology of Fibrosis in Systemic Sclerosis.- Overview of Animal Models.- Section IV. Cardiovascular Manifestations and Management.- Raynaud’s Phenomenon, Digital Ulcers, and Nailfold Capillaroscopy.- Renal Crisis and Other Renal Manifestations of Scleroderma.- Cardiac Involvement.- Section V. Pulmonary Manifestations and Management.- Overview of Lung Involvement: Diagnosis, Differential Diagnosis, and Monitoring.- Clinical Assessment of Lung Disease.- Treatment of Interstitial Lung Disease.- Pathogenesis of Pulmonary Arterial Hypertension.- Clinical Assessment of Pulmonary Hypertension.- The Management of Pulmonary Arterial Hypertension in the Setting of Systemic Sclerosis.- Section VI. Gastrointestinal Manifestations and Management.- Overview of Gastrointestinal Tract Involvement.- Upper Gastrointestinal Tract: Manifestations of Systemic Sclerosis.- Small and Large Intestinal Involvement and Nutritional Issues.- Section VII. Skin, Musculoskeletal and Other Complications.- Calcinosis.- Evaluation and Management of Skin Disease.- Assessment and Management of Progressive Skin Involvement in Diffuse Scleroderma.- Skeletal Muscle Involvement.- Tendons, Joints, and Bone.- Cancer in Systemic Sclerosis.- Overlooked  Manifestations.- Pregnancy.- Section VIII:  Management and Outcome Assessment.- Introduction to Section VIII: Management and Outcome Assessment.- Immunomodulatory, Immunoablative, and Biologic Therapies.- Investigative Approaches to Drug Therapy.- Drug Development and Regulatory Considerations for SSc Therapies.- Physical and Occupational Therapy.- Psychosocial Issues and Care for Patients with Systemic Sclerosis.- Clinical Trial Design in Systemic Sclerosis.- Measuring Disease Activity and Outcomes in Clinical Trials.- Innovative Approaches to Clinical Trials in Systemic Sclerosis.- Molecular Stratification by Gene Expression as a Paradigm for Precision Medicine in Systemic Sclerosis.- Section IX. Case Studies: Approach to Complex Clinical Problems.- Managing the Ischemic Finger in Scleroderma.- Scleroderma Renal Crisis.- Rapid Diffuse Skin Disease with Progressive Joint Contractures.- Management of the Scleroderma Patient with Pulmonary Arterial Hypertension Failing Initial Therapy.- Pseudo-obstruction with Malabsorption and Malnutrition.- Progressive Interstitial Lung Disease Non-Response to Cyclophosphamide.- Coping with the Disfigurement of Scleroderma: Facial, Skin, and Hand Changes.- Managing Complicated Digital Ulcers